Skip to main content
. 2015 Dec 14;34(4):329–336. doi: 10.1200/JCO.2015.63.3826

Fig A1.

Fig A1.

Association between pretransplant disease status and outcome for patients with acute myeloid leukemia (AML) undergoing myeloablative hematopoietic cell transplantation (HCT) while in morphologic remission. Estimates of (A) overall survival and (B) progression-free survival after myeloablative allogeneic HCT for adults with AML, shown individually for patients in minimal residual disease (MRD)–negative remission 1 (n = 181), MRD-negative remission 2 (n = 54), MRD-positive remission 1 (n = 51), and MRD-positive remission 2 (n = 25). neg, negative; pos, positive.